
IVEVF
Healthcare · Biotechnology · $760.3M market cap
$3.180.00 (0.0%)Nov 13, 9:30 AM EST
Latest report
After the close
The next earnings date isn’t on the calendar yet.
Analyst consensus
Fiscal period ending Sep 30, 2026
EPS trend, 90 days to now
Beat estimates in 3 of the last 4 reported quarters.
EPS surprise versus the estimate at the time of the report.
| Date | Session | Estimate | Actual | Surprise |
|---|---|---|---|---|
| May 12, 2021 | After the close | -0.27 | -0.44 | -62.4% |
| Mar 15, 2021 | Before the open | -0.68 | -0.27 | +60.5% |
| Nov 12, 2020 | After the close | -0.32 | -0.29 | +9.4% |
| Jul 6, 2020 | After the close | -0.70 | -0.28 | +60.3% |
| May 14, 2020 | Before the open | — | -0.26 | — |
| Mar 10, 2020 | Before the open | 0.00 | -0.26 | — |
| Nov 13, 2019 | Before the open | 0.00 | -0.22 | — |
| Sep 25, 2019 | Before the open | 0.00 | -0.21 | — |
| May 15, 2019 | Before the open | 0.00 | -0.56 | — |
| Feb 27, 2019 | Before the open | 0.00 | -0.49 | — |
| Nov 13, 2018 | Before the open | 0.00 | -0.43 | — |
| Sep 27, 2018 | Before the open | 0.00 | -0.44 | — |
| May 15, 2018 | Before the open | 0.00 | -0.50 | — |
Inventiva S.A., a clinical-stage biopharmaceutical company, focuses on the development of oral small molecule therapies for the treatment of metabolic dysfunction-associated steatohepatitis (MASH) and other diseases in France and internationally. It develops Lanifibranor, a novel peroxisome proliferator-activated receptor agonist that is in the NATiV3 Phase 3 clinical trial to treat adult patients with MASH; and…
| Mar 7, 2018 |
| Before the open |
| 0.00 |
| -0.53 |
| — |